Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Nanoparticle-Based Therapeutic Applications and Detection of Carbon Monoxide Releasing Molecules

Project description

Safer and more effective use of carbon monoxide to treat a host of pathologies

Until recently, carbon monoxide (CO) was studied primarily for its toxic effects, impeding the delivery of oxygen to tissues. It is now known to have a protective homeostatic effect against diseases at low concentrations. Inhalable CO-releasing molecules (CORMs) are being actively developed as therapeutics, yet they face challenges in terms of tissue specificity and potential heavy metal toxicity. The EU-funded ACORN project will address these challenges with MRI and optical imaging monitoring methodologies, encapsulation of CORMs inside FDA-approved nanocarriers, and conjugation of peptide molecules to the surface of the nanocarriers to target delivery.

Objective

Carbon monoxide (CO) has gathered increasing attention because of its role as a gasotransmitter with therapeutic and cell-protective effects. It is also recognised as a cell-signalling molecule where recent developments in the area of CO-releasing molecules (CORMs) and materials for controlled CO application have shown their importance with respect to delivery of such agents to their respective targets. However, despite their promise, their remains two major bottlenecks that may prevent these compounds from reaching the clinic. Firstly, the precise spatial-temporal CO release of CORMs is not target-specific. The CO molecule is highly diffusive and binds to haemoproteins, which are ubiquitous. Secondly, CORMs are made of metal carbonyl complexes and as organometallic compounds, there is the potential of heavy metal toxicity. Moreover, since CORMs are water-soluble they are distributed throughout the body, which can lead to further increased toxicities against healthy tissues. Our project aims to alleviate some of the problems of CORMs by a) developing a method to monitor CO release by MRI and optical imaging; b) reformulate CORMs by encapsulating inside nanomaterials (specifically the FDA approved PLGA as a nanocarrier) and c) provide targeting of the CORMs to their site of delivery by conjugating peptide targeting moieties to the surface of the PLGA nanoparticle. Through the completion of these activities, I;;, supported by its twinning partners, is in the best position to achieve an improved capability to compete for internationally competitive research funding and to access business stakeholders. By claiming its position in research and innovation networks IMM will effectively contribute to research excellence and value creation in health at European level.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSA - Coordination and support action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-WIDESPREAD-2016-2017

See all projects funded under this call

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 353 750,00
Address
AVENIDA PROF EGAS MONIZ
1649 028 Lisboa
Portugal

See on map

Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 353 750,00

Participants (5)

My booklet 0 0